I-01 Andrijana Radivojevic Enhancing population PK modeling efficiency using an integrated workflow Wednesday 10:05-11:40 |
I-02 Gauri Rao A Proposed Adaptive Feedback Control (AFC) Algorithm for Linezolid (L) based on Population Pharmacokinetics (PK)/Pharmacodynamics (PD)/Toxicodynamics(TD) Wednesday 10:05-11:40 |
I-03 Sylvie Retout A drug development tool for trial simulation in prodromal Alzheimer’s patient using the Clinical Dementia Rating scale Sum of Boxes score (CDR-SOB). Wednesday 10:05-11:40 |
I-04 Philippe Jacqmin Constructing the disease trajectory of CDR-SOB in Alzheimer’s disease progression modelling Wednesday 10:05-11:40 |
I-05 Rachel Rose Application of a Physiologically Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model to Investigate the Effect of OATP1B1 Genotypes on the Cholesterol Synthesis Inhibitory Effect of Rosuvastatin Wednesday 10:05-11:40 |
I-06 Elisabeth Rouits Population pharmacokinetic model for Debio 1143, a novel antagonist of IAPs in cancer treatment Wednesday 10:05-11:40 |
I-07 Alberto Russu Second-order indirect response modelling of complex biomarker dynamics Wednesday 10:05-11:40 |
I-08 Teijo Saari Pharmacokinetics of free hydromorphone concentrations in patients after cardiac surgery Wednesday 10:05-11:40 |
I-09 Tarjinder Sahota Real data comparisons of NONMEM 7.2 estimation methods with parallel processing on target-mediated drug disposition models Wednesday 10:05-11:40 |
I-10 Maria Luisa Sardu Tumour Growth Inhibition In Preclinical Animal Studies: Steady-State Analysis Of Biomarker-Driven Models. Wednesday 10:05-11:40 |
I-11 Emilie Schindler PKPD-Modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size following axitinib treatment in metastatic renal cell carcinoma (mRCC) patients Wednesday 10:05-11:40 |
I-12 Alessandro Schipani Population pharmacokinetic of rifampicine in Malawian children. Wednesday 10:05-11:40 |
I-13 Henning Schmidt The “SBPOP Package”: Efficient Support for Model Based Drug Development – From Mechanistic Models to Complex Trial Simulation Wednesday 10:05-11:40 |
I-14 Stephan Schmidt Mechanistic Prediction of Acetaminophen Metabolism and Pharmacokinetics in Children using a Physiologically-Based Pharmacokinetic (PBPK) Modeling Approach Wednesday 10:05-11:40 |
I-15 Rik Schoemaker Scaling brivaracetam pharmacokinetic parameters from adult to pediatric epilepsy patients Wednesday 10:05-11:40 |
I-16 Seonghae Yoon Population pharmacokinetic analysis of two different formulations of tacrolimus in stable pediatric kidney transplant recipients Wednesday 10:05-11:40 |
I-17 Catherine Sherwin Dense Data - Methods to Handle Massive Data Sets without Compromise Wednesday 10:05-11:40 |
I-18 Giovanni Smania Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation Wednesday 10:05-11:40 |
I-19 Alexander Solms Translating physiologically based Parameterization and Inter-Individual Variability into the Analysis of Population Pharmacokinetics Wednesday 10:05-11:40 |
I-20 Hankil Son A conditional repeated time-to-event analysis of onset and retention times of sildenafil erectile response Wednesday 10:05-11:40 |
I-21 Heiner Speth Referenced Visual Predictive Check (rVPC) Wednesday 10:05-11:40 |
I-22 Michael Spigarelli Title: Rapid Repeat Dosing of Zolpidem - Apparent Kinetic Change Between Doses Wednesday 10:05-11:40 |
I-23 Christine Staatz Dosage individulisation of tacroliums in adult kidney transplant recipients Wednesday 10:05-11:40 |
I-24 Gabriel Stillemans A generic population pharmacokinetic model for tacrolimus in pediatric and adult kidney and liver allograft recipients Wednesday 10:05-11:40 |
I-25 Elisabet Størset Predicting tacrolimus doses early after kidney transplantation - superiority of theory based models Wednesday 10:05-11:40 |
I-26 Fran Stringer A Semi-Mechanistic Modeling approach to support Phase III dose selection for TAK-875 Integrating Glucose and HbA1c Data in Japanese Type 2 Diabetes Patients Wednesday 10:05-11:40 |
I-27 Eric Strömberg FIM approximation, spreading of optimal sampling times and their effect on parameter bias and precision. Wednesday 10:05-11:40 |
I-28 Herbert Struemper Population pharmacokinetics of belimumab in systemic lupus erythematosus: insights for monoclonal antibody covariate modeling from a large data set Wednesday 10:05-11:40 |
I-29 Elin Svensson Individualization of fixed-dose combination (FDC) regimens - methodology and application to pediatric tuberculosis Wednesday 10:05-11:40 |
I-30 Eva Sverrisdottir Modelling analgesia-concentration relationships for morphine to evaluate experimental pain models Wednesday 10:05-11:40 |
I-31 Maciej Swat PharmML – An Exchange Standard for Models in Pharmacometrics Wednesday 10:05-11:40 |
I-32 Amit Taneja From Behaviour to Target: Evaluating the putative correlation between clinical pain scales and biomarkers. Wednesday 10:05-11:40 |
I-33 Joel Tarning The population pharmacokinetic and pharmacodynamic properties of intramuscular artesunate and quinine in Tanzanian children with severe falciparum malaria; implications for a practical dosing regimen. Wednesday 10:05-11:40 |
I-34 David Ternant Adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis Wednesday 10:05-11:40 |
I-35 Adrien Tessier High-throughput genetic screening and pharmacokinetic population modeling in drug development Wednesday 10:05-11:40 |
I-36 Iñaki F. Trocóniz Modelling and simulation applied to personalised medicine Wednesday 10:05-11:40 |
I-37 Nikolaos Tsamandouras A mechanistic population pharmacokinetic model for simvastatin and its active metabolite simvastatin acid Wednesday 10:05-11:40 |
I-38 Sebastian Ueckert AD i.d.e.a. – Alzheimer’s Disease integrated dynamic electronic assessment of Cognition Wednesday 10:05-11:40 |
I-39 Wanchana Ungphakorn Development of a Physiologically Based Pharmacokinetic Model for Children with Severe Malnutrition Wednesday 10:05-11:40 |
I-40 Elodie Valade Population Pharmacokinetics of Emtricitabine in HIV-1-infected Patients Wednesday 10:05-11:40 |
I-41 Georgia Valsami Population exchangeability in Bayesian dose individualization of oral Busulfan Wednesday 10:05-11:40 |
I-42 Sven van Dijkman Predicting antiepileptic drug concentrations for combination therapy in children with epilepsy. Wednesday 10:05-11:40 |
I-43 Coen van Hasselt Design and analysis of studies investigating the pharmacokinetics of anti-cancer agents during pregnancy Wednesday 10:05-11:40 |
I-44 Anne van Rongen Population pharmacokinetic model characterising the influence of circadian rhythm on the pharmacokinetics of oral and intravenous midazolam in healthy volunteers Wednesday 10:05-11:40 |
I-45 Marc Vandemeulebroecke Literature databases: integrating information on diseases and their treatments. Wednesday 10:05-11:40 |
I-46 Nieves Velez de Mendizabal A Population PK Model For Citalopram And Its Major Metabolite, N-desmethyl Citalopram, In Rats Wednesday 10:05-11:40 |
I-47 An Vermeulen Population Pharmacokinetic Analysis of Canagliflozin, an Orally Active Inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) Wednesday 10:05-11:40 |
I-48 Marie Vigan Modelling the evolution of two biomarkers in Gaucher patients receiving enzyme replacement therapy. Wednesday 10:05-11:40 |
I-49 Paul Vigneaux Extending Monolix to use models with Partial Differential Equations Wednesday 10:05-11:40 |
I-50 Winnie Vogt Paediatric PBPK drug-disease modelling and simulation towards optimisation of drug therapy: an example of milrinone for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery Wednesday 10:05-11:40 |
I-51 Max von Kleist Systems Pharmacology of Chain-Terminating Nucleoside Analogs Wednesday 10:05-11:40 |
I-52 Camille Vong Semi-mechanistic PKPD model of thrombocytopenia characterizing the effect of a new histone deacetylase inhibitor (HDACi) in development, in co-administration with doxorubicin. Wednesday 10:05-11:40 |
I-53 Katarina Vučićević Total plasma protein and haematocrit influence on tacrolimus clearance in kidney transplant patients - population pharmacokinetic approach Wednesday 10:05-11:40 |
I-54 Bing Wang Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and asthma patients Wednesday 10:05-11:40 |
I-55 Jixian Wang Design and analysis of randomized concentration controlled Wednesday 10:05-11:40 |
I-56 Franziska Weber A linear mixed effect model describing the expression of peroxisomal ABCD transporters in CD34+ stem cell-derived immune cells of X-linked Adrenoleukodystrophy and control populations Wednesday 10:05-11:40 |
I-57 Sebastian Weber PK/PD assessment of tacrolimus nephrotoxicity in liver transplantation Wednesday 10:05-11:40 |
I-58 Mélanie Wilbaux A drug-independent model predicting Progression-Free Survival to support early drug development in recurrent ovarian cancer Wednesday 10:05-11:40 |
I-59 Dan Wright Bayesian dose individualisation provides good control of warfarin dosing. Wednesday 10:05-11:40 |
I-60 Klintean Wunnapuk Population analysis of paraquat toxicokinetics in poisoning patients Wednesday 10:05-11:40 |
I-61 Rujia Xie Population PK-QT analysis across Phase I studies for a p38 mitogen activated protein kinase inhibitor – PH-797804 Wednesday 10:05-11:40 |
I-62 Shuying Yang First-order longitudinal population model of FEV1 data: single-trial modeling and meta-analysis Wednesday 10:05-11:40 |
I-63 Jiansong Yang Practical diagnostic plots in aiding model selection among the general model for target-mediated drug disposition (TMDD) and its approximations Wednesday 10:05-11:40 |
I-64 Rui Zhu Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy Wednesday 10:05-11:40 |